New York, NY -- (SBWIRE) -- 06/01/2015 -- Attention-deficit hyperactivity disorder (ADHD) refers to a developmental neuropsychiatric disorder owing to which a person loses control over her/his executive functions, including attentional and inhibitory control. As a result, it may lead to attention deficit, hyperactivity, or impulsiveness. Treatment for attention-deficit hyperactivity disorder includes medications, lifestyle changes, and counseling. This disorder is more common in children below 12 years of age and the cause behind this disorder is still unknown. Common symptoms for attention attention-deficit hyperactivity disorder are difficulty in maintaining focus on one task, being easily distracted, missing details, forgetting things, frequent tendencies to switch from one activity to another, impatience, being constantly in motion, and having difficulty in doing quiet tasks or activities. Medications for attention-deficit hyperactivity disorder may be classified into stimulants, nonstimulants, and others. The market for attention-deficit hyperactivity disorder therapeutics is increasing at a significant rate due to increasing number of attention-deficit hyperactivity disorder cases worldwide.

Buy Full Report: http://www.persistencemarketresearch.com/market-research/attention-deficit-hyperactivity-disorder-therapeutics-market.asp

North America dominates the global market for attention-deficit hyperactivity disorder therapeutics due to high prevalence of learning disabilities and better healthcare facilities available in the region, followed by Europe. In addition, high adoption rate of attention-deficit hyperactivity disorder therapeutics is driving the market in the region. Asia is expected to show high growth rate in the next few years in the attention-deficit hyperactivity disorder therapeutics market. China and India are expected to be the fastest growing regions in Asia. Some of the key driving forces of attention-deficit hyperactivity disorder therapeutics market in emerging countries are increasing R&D investment, large pool of patients, rising government funding, and growing awareness about attention-deficit hyperactivity disorder.

Various factors such as increasing patient pool with learning disability, rising awareness about attention-deficit hyperactivity disorder, and available treatment options are some of the key factors driving the attention-deficit hyperactivity disorder therapeutics market. Furthermore, government funding and introduction of safer and effective therapeutics for the treatment of attention-deficit hyperactivity disorder are also driving the attention-deficit hyperactivity disorder therapeutics market. However, factors such as high cost involved in treatment due to long medications, and less success rate are restraining the attention-deficit hyperactivity disorder therapeutics market. In addition, less adoption rate for attention-deficit hyperactivity disorder therapeutics in some regions restrains the market from growing.

Introduction of the concept of personalized medicines, mono-therapeutic approaches, or combination of therapies are expected to offer good opportunities to the attention-deficit hyperactivity disorder therapeutics market. In addition, growing demographics and economies in the developing countries such as India and China in Asia and other countries in South East Asia, Latin America, and the Middle East are expected to propel the growth of the attention-deficit hyperactivity disorder therapeutics market. A major trend that has been observed in attention-deficit hyperactivity disorder therapeutics market is that several pharmaceutical and biotechnology companies are engaged in the R&D of novel medications for the treatment of attention-deficit hyperactivity disorder. Key companies in the attention-deficit hyperactivity disorder therapeutics market are Eli Lilly and Company, Curemark, LLC., Johnson & Johnson, NextWave Pharmaceuticals, Novartis AG, and Shire Plc. In addition, other companies such as Takeda Pharmaceutical Company Limited, Signature Therapeutics, Inc., Reviva Pharmaceuticals, Inc., DURECT Corporation, Taisho Pharmaceutical Co., Ltd., Vernalis Plc, and NeuroDerm, Ltd. have significant presence in the attention-deficit hyperactivity disorder market.

Request Full Toc: http://www.persistencemarketresearch.com/toc/4222

Key points covered in the report:

1) Report segments the market on the basis of types, application, products, technology, etc (as applicable)

2) The report covers geographic segmentation

North America
Europe
Asia
RoW

3) The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020

4) The report provides company profiles of some of the leading companies operating in the market

The report also provides porters five forces analysis of the market.

Visit our blog at: http://pmrblog.com/

About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.